

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 9/30/1960  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**TFE3 Gene Rearrangement by FISH**

ARUP test code 3002633

TFE3 Ref Number 1234

TFE3 Source Kidney

TFE3 Result Negative

This result has been reviewed and approved by Georgios Deftereos, M.D. Controls performed as expected.

**INTERPRETIVE INFORMATION: TFE3 Gene Rearrangements by FISH**

Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block using differentially labeled fluorescent probes targeting the upstream (5'lochflhichf1'92) and downstream (3'92) flanking regions of the TFE3 gene (Zytovision GmbH). Cells were evaluated from regions of tumor identified on histopathologic review of a matching hematoxylin- and eosin-stained section. Controls performed appropriately.

This test is designed to detect translocations involving the TFE3 gene but does not identify a specific translocation partner. An abnormal signal pattern seen in 15 percent or more of the tumor cells evaluated is considered a positive result. While this test can detect most rearrangements it may not be able to detect rare cryptic rearrangements and intrachromosomal inversion events, such as a RBM10-TFE3 fusion. Based on the assay performance during test validation, the test is expected to detect 100 percent of TFE3 rearrangements in patients with TFE3-rearranged carcinomas, except for rare instances of cryptic rearrangements. Assay range and limit of detection were generated using normal and known positive cases respectively.

Identification of a rearrangement of the TFE3 gene locus is useful for the diagnosis of Alveolar Soft Part Sarcoma (ASPS) and Xp11 Translocation Renal Cell Carcinoma. TFE3 rearrangements are also identified in other neoplasms, including perivascular epithelioid cell tumors (PEComa) and epithelioid hemangioendotheliomas (EHE).

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

Total Cell Count 100

H=High, L=Low, \*=Abnormal, C=Critical

Scoring Method

Manual

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
TFE3 Ref Number	20-192-150329	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
TFE3 Source	20-192-150329	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
TFE3 Result	20-192-150329	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Total Cell Count	20-192-150329	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Scoring Method	20-192-150329	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical